AbbVie acquires Bain-backed Cerevel in $8.7bn deal
Cerevel Therapeutics Holdings, a developer of drugs for neurological conditions such as Parkinson’s, is to be acquired by AbbVie Inc in a deal worth around $8.7bn. Private investment firm Bain Capital is Nasdaq-listed Cerevel’s largest shareholder.